PiL-Obs-RSDep-015

About this trial

Last updated 7 years ago

Study ID

PiL-Obs-RSDep-015

Status

Completed

Type

Observational

Placebo

Accepting

18 to 85 Years

All

Not accepting

Healthy Volunteers

Trial Timing

Ended 8 years ago

The purpose of the study is to describe, over 6 weeks, the evolution of depressive symptoms in patients with mild to moderate major depression in a strategy with Phytostandard® Rhodiola-Saffron supplementation

Inclusion Criteria

- Suffering from mild to moderate depression as defined in CIM-10

- Having a score on the HAM-D questionnaire between 8 and 18

- Having agreed to participate at the study after being informed by the investigator

Exclusion Criteria

- Depressive patients already under medication or discontinuation of medication less than a month ago

- Patients with severe depression as defined in CIM-10 or HAM-D> 18

- Patients considered at risk: attempted suicide or suicidal (observed by the investigator or Hamilton item 3 score> 2)

- Patients with psychiatric disorders: schizophrenia, bipolarity, addiction (drugs, alcohol ...), etc.

- Patient with severe disease (cancer, kidney or heart disease) or patient with a contra-indication for taking the product (patient under anti-hypertensive ...)

- Patients using agents containing piperine or St. John's wort (interactions)

- Pregnant or breastfeeding patients

- Patients who do not wish to complement Phytostandard® Rhodiola - Saffron.

- Patients who do not wish to participate in the study.

- Patients unable to understand the ins and outs of the study (mental incapacity, language barrier).

Management Strategy for Mild to Moderate Major Depression: Combination of Rhodiola and Saffron Extracts.